Method of detection of alterations in MSH5
We have now discovered that mammals have a DNA gene analogous to that existing in bacteria. MSH5 defects or alterations in this mismatch repair pathway in a mammal, such as a human, can be diagnostic of a predisposition to cancer, and prognostic for a particular cancer: We have discovered and sequenced MSH5 in a number of mammals, including humans. This gene can be used in assays, to express gene product, for drug screens, and therapeutically.
1. A method of determining an alteration in a nucleic acid encoding human MSH5 gene, wherein said human MSH5 is encoded by SEQ ID No.: 1, the method comprising analyzing a nucleic acid in a biological sample for an alteration in the SEQ ID No.: 1 by comparing the nucleic acid in the biological sample to that of the sequence of SEQ ID NO: 1 wherein a difference in the nucleic acid in the sample compared to SEQ ID NO: 1 represents an alteration in human MSH5 gene.
2. The method of claim 1 , wherein the biological sample is selected from blood, tissue, serum, stool, urine, sputum, cerebrospinal fluid, supernatant from cell lysate and a eukaryotic cell sample.
3. The method of claim 1 , wherein the analyzing is performed using mRNA in the biological sample.
4. The method of claim 1 , wherein the analyzing is performed using DNA in the biological sample.
5. The method of claim 1 , wherein the biological sample is from an individual affected with cancer.
6. The method of claim 1 , wherein the biological sample is from an individual affected with infertility.
7. The method of claim 1 , wherein the alteration is detected using a pair of oligonucleotide primers that hybridize to SEQ ID NOs: 3-26 or 27-50.
8. The method of claim 1 , wherein the analysis is performed using nucleic acid sequencing.
9. The method of claim 1 , wherein the comparison is made by looking at a genomic sample by looking at at least one individual exon.
10. The method of claim 1 , wherein the alteration is determined using restriction fragment length polymorphism using a probe or probes that specifically bind to SEQ ID NO: 1.
11. The method of claim 1 , wherein the alteration is a deletion within SEQ ID NO: 1.
12. The method of claim 1 , wherein the alteration is a point mutation within SEQ ID NO: 1.
13. A method of determining an alteration in a nucleic acid encoding human MSH5 comprising the steps of
(a) amplifying a nucleic acid from a biological sample with primers that specifically hybridize to SEQ ID NO:1; and
(b) comparing the amplified nucleic acid to SEQ ID NO: 1,
wherein a difference in the nucleic acid from the biological sample compared to the corresponding sequence region in SEQ ID NO: 1 is indicative of an alteration in the nucleic acid encoding human MSH5.
14. The method of claim 13 , wherein at least one pair of the primers specifically hybridize to one of the exon/intron borders of human MSH5.
15. The method of claim 14 , wherein the human MSH5 exon/intron borders are selected from SEQ ID NOs: 3-26 and 27-50.
16. The method of claim 1 , wherein the comparison is made by looking at a coding region of the SEQ ID NO: 1.
17. The method of claim 1 , wherein the comparison is made by looking at a non-coding region of the SEQ ID NO: 1.